BioCentury
ARTICLE | Product Development

Incyte continues layering on new opportunities

Incyte ramps up portfolio expansion with push into dermatology

February 6, 2021 1:42 AM UTC

The next stage of Incyte’s growth strategy is already well under way as the company continues to expand its cancer portfolio and prepares to bring its first dermatology program to market. 

Much of the current value of the $20 billion midcap biotech is centered around its leading myelofibrosis franchise, Jakafi ruxolitinib, which accounted for 90% of the company’s revenues in the first nine months of 2020...

BCIQ Company Profiles

Incyte Corp.